Phase I/II Study of Ublituximab in Combination With Lenalidomide (Revlimid(RM)) in Patients With B-Cell Lymphoid Malignancies Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2014
At a glance
- Drugs Ublituximab (Primary) ; Lenalidomide
- Indications B cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors TG Therapeutics Inc
- 12 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Nov 2013 Planned end date changed from 1 Feb 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.